IRIS Institutional Research Information System - OPENBS Open Archive UniBS

BELLUCCI, ARIANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.853
EU - Europa 4.431
AS - Asia 3.832
SA - Sud America 637
Continente sconosciuto - Info sul continente non disponibili 390
AF - Africa 94
OC - Oceania 12
Totale 16.249
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.721
PL - Polonia 1.629
SG - Singapore 1.277
CN - Cina 1.260
IT - Italia 638
UA - Ucraina 571
BR - Brasile 532
DE - Germania 437
HK - Hong Kong 404
VN - Vietnam 300
FI - Finlandia 272
FR - Francia 221
GB - Regno Unito 197
RU - Federazione Russa 130
TR - Turchia 127
IN - India 126
IE - Irlanda 110
BD - Bangladesh 99
CA - Canada 67
MX - Messico 38
NL - Olanda 36
ID - Indonesia 35
IQ - Iraq 34
SE - Svezia 34
AR - Argentina 32
KR - Corea 30
ZA - Sudafrica 28
BE - Belgio 26
CZ - Repubblica Ceca 26
JP - Giappone 24
ES - Italia 22
AT - Austria 17
PK - Pakistan 17
EC - Ecuador 16
VE - Venezuela 14
CO - Colombia 13
IL - Israele 12
KE - Kenya 12
UZ - Uzbekistan 12
AU - Australia 11
CH - Svizzera 10
JO - Giordania 10
AZ - Azerbaigian 9
EG - Egitto 9
MA - Marocco 9
NG - Nigeria 9
PY - Paraguay 9
PE - Perù 8
BG - Bulgaria 7
SK - Slovacchia (Repubblica Slovacca) 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
IR - Iran 6
LT - Lituania 6
BY - Bielorussia 5
CL - Cile 5
DZ - Algeria 5
ET - Etiopia 5
EU - Europa 5
GT - Guatemala 5
HN - Honduras 5
PT - Portogallo 5
SA - Arabia Saudita 5
CR - Costa Rica 4
JM - Giamaica 4
KZ - Kazakistan 4
UY - Uruguay 4
AM - Armenia 3
BO - Bolivia 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
EE - Estonia 3
GR - Grecia 3
HU - Ungheria 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
MU - Mauritius 3
MY - Malesia 3
NP - Nepal 3
OM - Oman 3
PS - Palestinian Territory 3
RO - Romania 3
CY - Cipro 2
HR - Croazia 2
KG - Kirghizistan 2
LB - Libano 2
NI - Nicaragua 2
PA - Panama 2
SN - Senegal 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CM - Camerun 1
GE - Georgia 1
GY - Guiana 1
Totale 15.852
Salva come PNG Salva come JPEG
Città #
Warsaw 1.624
Singapore 696
Ashburn 605
Fairfield 561
Woodbridge 427
Jacksonville 421
Hong Kong 403
San Jose 308
Chandler 292
Beijing 270
Dearborn 270
Houston 251
Cambridge 245
Seattle 226
Brescia 224
The Dalles 220
Ann Arbor 207
Wilmington 202
Princeton 192
Helsinki 180
New York 171
Council Bluffs 153
Nanjing 145
Los Angeles 116
Dublin 109
Lauterbourg 100
Munich 100
Istanbul 95
Ho Chi Minh City 83
Columbus 81
Milan 73
Dallas 67
Dong Ket 66
Des Moines 58
São Paulo 57
Santa Clara 53
Buffalo 52
San Francisco 51
Jinan 50
Moscow 48
Nanchang 48
Shanghai 47
Chicago 46
Hanoi 45
Changsha 43
Hebei 40
Shenyang 39
Pune 38
Orem 36
Tianjin 34
Boardman 32
Redondo Beach 31
San Diego 31
Denver 29
London 29
Jakarta 27
Turku 27
Brussels 25
Frankfurt am Main 25
Phoenix 24
Kunming 23
Toronto 23
Atlanta 22
Rome 22
Tokyo 22
Rio de Janeiro 20
Hangzhou 19
Brno 18
Guangzhou 18
Jiaxing 18
Nuremberg 18
Brooklyn 17
Ningbo 17
Poplar 16
Taizhou 16
Lappeenranta 15
Stockholm 14
Tucson 14
Zhengzhou 14
Ankara 13
Baghdad 13
Montreal 13
San Giuliano Milanese 13
Boston 12
Haiphong 12
Johannesburg 12
Manchester 12
Nairobi 12
Tashkent 12
Verona 12
Belo Horizonte 11
Dhaka 11
Hefei 11
Lanzhou 11
Mexico City 11
Norwalk 11
Paris 11
Amman 10
Amsterdam 10
Brasília 10
Totale 10.837
Salva come PNG Salva come JPEG
Nome #
Anionic liposomes for siRNA delivery to primary neuronal cells: evaluation of Alpha synuclein knockdown efficacy 382
Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation 366
Redistribution of DAT/α-synuclein complexes visualized by “in situ” proximity ligation assay in transgenic mice modelling early Parkinson’s disease 323
Dopamine transporter/α-synuclein complexes are altered in the post mortem caudate putamen of Parkinson’s disease: An in situ proximity ligation assay study 306
NF-κB in Innate Neuroprotection and Age-Related Neurodegenerative Diseases 292
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. 282
INDUCTION OF INFLAMMATORY MEDIATORS AND MICROGLIAL ACTIVATION IN MICE TRANSGENIC FOR MUTANT P301S TAU PROTEIN 279
Mild inflammatory profile without gliosis in the c-rel deficient mouse modeling a late-onset parkinsonism 270
The End Is the Beginning: Parkinson's Disease in the Light of Brain Imaging 268
The Contribution of -Synuclein Spreading to Parkinson’s Disease Synaptopathy 263
The "in situ" proximity ligation assay to probe protein-protein interactions in intact tissues 229
Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure 227
Alpha-Synuclein Preserves Mitochondrial Fusion and Function in Neuronal Cells 227
Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate 225
null 222
Mitochondria and alpha-synuclein: Friends or foes in the pathogenesis of Parkinson's disease? 210
Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains 209
NF-κB/c-Rel deficiency causes Parkinson's disease-like prodromal symptoms and progressive pathology in mice 208
c-Rel deficient mice, a mouse model of "spreading" PD-like pathology. 199
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines 197
Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation 193
The proximity ligation assay: an high throughput technique for protein analysis in neuroscience 185
α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons 178
From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease 175
Depletion of Progranulin Reduces GluN2B-Containing NMDA Receptor Density, Tau Phosphorylation, and Dendritic Arborization in Mouse Primary Cortical Neurons 175
c-Rel deficient mice, a mouse model of “spreading” PD-like pathology 172
Synapsin III alterations in Parkinson's disease 168
Point mutated Caveolin-3 form (P104L) impairs myoblast differentiation via Akt and p38 signalling reduction, leading to an immature cell signature 166
Mitochondrial Dysfunction and Alpha-Synuclein Synaptic Pathology in Parkinson’s Disease: Who’s on First? 166
Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases 164
DIFFERENTIAL ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE SIGNALLING PATHWAYS IN THE HIPPOCAMPUS OF CRND8 TRANSGENIC MOUSE, A MODEL OF ALZHEIMER'S DISEASE 163
ALPHA-SYNUCLEIN MODULATES SYNAPSIN III IN NIGROSTRIATAL DOPAMINERGIC NEURONS: IMPLICATIONS FOR PARKINSON'S DISEASE 161
Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy 161
EFFECT OF SUBCHRONIC ADMINISTRATION OF METRIFONATE, RIVASTIGMINE AND DONEPEZIL ON BRAIN ACETYLCHOLINE IN AGED F344 RATS 157
Involvement of Synapsin III in the onset of alpha-synuclein synaptic pathology in Parkinson’s disease 154
Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer 154
Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of Parkinson’s disease and dementia with Lewy bodies, 150
Design and Synthesis of Fluorescent Methylphenidate Analogues for a FRET-Based Assay of Synapsin III Binding 149
Synapsin III Alteration in Parkinson's disease 146
PGRN gene silencing in primary neuronal cultures: a model of FTLD-U 145
AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons of Synapsin III knockout mice reveals novel molecular features involved in Parkinson's disease pathology. 143
Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson’s Disease 143
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. 142
Involvement of Synapsin III in the onset of Alpha-synuclein pathology in Parkinson’s Disease 142
ABNORMAL PROCESSING OF TAU IN THE BRAIN OF AGED TGCRND8 MICE 141
Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives 141
ANALOGHI STRUTTURALI DEL METILFENIDATO COME AGENTI DISEASE-MODIFYING DELLA MALATTIA DI PARKINSON 140
Synapsin III Alteration in Parkinson's disease 138
COMBINED TREATMENT WITH ATORVASTATIN AND MINOCYCLINE SUPPRESSES SEVERITY OF EAE 137
Alpha-synuclein and NMDA receptors: a novel postsynaptic couple playing a pivotal role in the regulation of the functional activity of nigral dopaminergic neurons 137
Presence of Reactive Microglia and Neuroinflammatory Mediators in a Case of Frontotemporal Dementia with P301S Mutation. 136
Alpha-synuclein modulates the localization, expression and function of NR2B-containing NMDA receptors: implications in the pathogenesis of Parkinson's disease 134
Alpha-synuclein aggregation in dopaminergic cells is modulated by glucose metabolism 131
Role of dopamine D3R and acetylcholine nicotinic receptor interaction in the regulation of dopaminergic neurons function. 131
An updated reappraisal of synapsins: structure, function and role in neurological and psychiatric disorders 131
Synapsin III and Alpha-Synuclein cooperation in the onset of synaptic pathology in Parkinson’s Disease 129
Exploring LRRK2-dependent clearance of α-synuclein pffs in glial cells via clusterin 129
Extracellular clusterin limits the uptake of α-synuclein fibrils by murine and human astrocytes 129
Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson’s disease 128
NF-κB unbalance and dysfunction in acute and age-related neurodegenerative disease 127
A novel stable transgenic zebrafish line expressing mCherry-tagged human alpha-synuclein in the nervous system and exhibiting all the key features of Lewy body disorders at larval stage 125
Synapsin III knock-out reduces AAV-alpha-synuclein overexpression-related neuropathology in the nigrostriatal system 123
The good and bad of therapeutic strategies that directly target α-synuclein 123
CHOLINERGIC DYSFUNCTION, NEURONAL DAMAGE AND AXONAL LOSS IN TGCRND8 MICE 120
Role of dopamine D3R/nAChR heterodimeric complex in the regulation of dopaminergic neurons function. 120
Parkinson's disease: from synaptic loss to connectome dysfunction 117
. Alpha-synuclein is a crucial mediator of mitochondrial fusion and functions 115
Study of alpha-synuclein fibrillation: State of the art and expectations 113
MicroRNA‑34a‑5p expression in the plasma and its extracellular vesicle fractions in subjects with Parkinson's disease: An exploratory study 112
Neuroprotective epi-drugs quench the inflammatory response and microglial/macrophage activation in a mouse model of permanent brain ischemia 111
NF-κB/c-Rel DNA-binding is reduced in substantia nigra and peripheral blood mononuclear cells of Parkinson's disease patients 109
Selective dopaminergic alpha-synuclein pathological changes following glucose deprivation "in vitro": implications for Parkinson's disease 109
Effects of rofecoxib treatment on brain inflammatory reaction and cholinergic function in beta-(1-42) injected rats into the nucleus basalis 108
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease 108
Non-steroid antiinflammatory agents (nsaids): are they a valid approach to Alzheimer’s disease prevention? 103
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson’s disease 103
Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson’s Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice 100
BETA-AMYLOID INFLAMMATION AND CHOLINERGIC HYPOFUNCTION IN THE RAT BRAIN IN VIVO: INVOLVEMENT OF P38MAPK PATHWAY 100
Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease. 100
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and synaptic protein’s redistribution 100
Alpha-Synuclein is Involved in DYT1 Dystonia Striatal Synaptic Dysfunction 99
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy? 99
Alpha-synuclein absence affected mitochondrial fusion and functions 99
The contribution of β-amyloid, Tau and α-synuclein to blood–brain barrier damage in neurodegenerative disorders 97
Redistribution of DAT/alpha-synuclein complexes visualized "in situ" by proximity ligation assay in a transgenic mouse model of Parkinson's disease 97
THE SELECTIVE CYCLOOXIGENASE-2 INHIBITOR ROFECOXIB SUPPRESSES BRAIN INFLAMMATION AND PROTECTS CHOLINERGIC NEURONS FROM EXCITOTOXIC DEGENERATION IN VIVO 95
In vivo effects of NSAIDs on amyloid beta(1-42)-induced brain neurotoxicity 94
Ex vivo characterization of progranulin gene silencing in primary neuronal cultures to study the biological basis of FTLD-U 92
Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease 90
NSAIDs in Animal Models of Alzheimer's disease 90
NSAIDs in animal models of Alzheimer’s Disease 89
Targeting α-Synuclein-Related Synaptic Pathology: Novel Clues for Parkinson’s Disease Therapy 88
Effects of novel NSAIDs on brain inflammation and release of neurotrasmitters in animal models of neurodegeneration 88
Neuroprotective effects of D2/D3 agonists in an "in vitro" model of dopaminergic degeneration 87
EXPERIMENTAL BRAIN INFLAMMATION AND NEURODEGENERATION AS MODEL OF ALZHEIMER'S DISEASE: PROTECTIVE EFFECTS OF SELECTIVE COX-2 INHIBITORS 86
Changes in α-Synuclein Posttranslational Modifications in an AAV-Based Mouse Model of Parkinson's Disease 85
Early α-synuclein/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease 85
Novel perspectives for Parkinson’s disease therapy: insights from the latest advances in disease pathophysiology, diagnostic and experimental tools and molecular targets 85
Validation of synapsin III as a therapeutic target for Parkinson’s disease in the AAV-mediated alpha-synuclein mouse model 85
Induction of the Unfolded Protein Response by alpha-synuclein in experimental models of Parkinson's disease 83
Totale 15.207
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.660
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.660
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022761 0 153 31 32 9 46 33 62 34 80 92 189
2022/2023866 125 10 30 63 90 212 7 99 132 21 39 38
2023/2024967 63 20 91 60 57 177 46 50 185 20 32 166
2024/20252.168 15 36 35 257 238 156 231 103 247 158 395 297
2025/20264.507 393 511 307 689 495 398 693 168 237 364 193 59
2026/2027293 178 115 0 0 0 0 0 0 0 0 0 0
Totale 16.249